Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 9/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17654143 | 0.88 | GLS (0.45) | GLSSMN1; SMN2ATM | |
| SCHEMBL17654135 | 0.88 | GLS (0.45) | GLSSMN1; SMN2ATM | |
| SCHEMBL17654137 | 0.88 | GLS (0.45) | GLSSMN1; SMN2ATM | |
| SCHEMBL17654163 | 0.86 | GLS (0.41) | GLSSMN1; SMN2ATM | |
| SCHEMBL17654154 | 0.84 | GLS (0.46) | GLSSMN1; SMN2ATM | |
| SCHEMBL17664629 | 0.80 | GPR119 (0.43) | GLS | |
| SCHEMBL17654116 | 0.75 | GLS (0.41) | GLSSMN1; SMN2ATMHTTHSD17B10 | |
| SCHEMBL17654171 | 0.75 | GLS (0.41) | GLSSMN1; SMN2ATMHTTHSD17B10 | |
| SCHEMBL31083338 | 0.74 | GLS (0.46) | GLSSMN1; SMN2 | |
| SCHEMBL17654083 | 0.73 | GLS (0.54) | GLSSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013724-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-05-25 | — | — | US | disclosed |
| US-20190167648-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-06-06 | — | — | US | disclosed |
| US-10245254-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-12 | — | — | US | disclosed |
| WO-2016054388-A1 | GLUTAMINASE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290815-A1 | GLUTAMINASE INHIBITORS | GLUL, ASNS, GLS | GLS 3/4885SMN1; SMN2 3248/4885ATM 3289/4885 |
| US-10245254-B2 | Glutaminase inhibitors | GLUL, ASNS, GLS | GLS 3/4885SMN1; SMN2 3248/4885ATM 3289/4885 |
| US-20190167648-A1 | GLUTAMINASE INHIBITORS | GLUL, ASNS, GLS | GLS 3/4885SMN1; SMN2 3228/4885ATM 3238/4885 |
| US-11013724-B2 | Glutaminase inhibitors | GLUL, ASNS, GLS | GLS 3/4885SMN1; SMN2 3228/4885ATM 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.